TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.45
-0.07 (-0.82%)
Apr 28, 2026, 4:00 PM EDT - Market closed
TransCode Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The meeting confirmed a quorum, elected four directors, and approved all proposals, including an increase in stock options and auditor ratification. A shareholder Q&A addressed clinical trial participation, with further results expected in September.
-
A quorum was established and two proposals—a reverse stock split and potential adjournment—were approved by majority vote. Stakeholders' questions focused on clinical trial data reporting and NIH grant funding, with assurances of timely updates and no current funding impact.